Patents Assigned to Encore Health, LLC
-
Patent number: 9567314Abstract: Dithiol compounds and derivatives thereof are disclosed. The agents are useful for treating ocular disease, especially presbyopia and cataract.Type: GrantFiled: March 11, 2016Date of Patent: February 14, 2017Assignee: Encore Health LLCInventors: William Garner, Margaret Garner, George Minno, David Gooden
-
Patent number: 9517225Abstract: Compositions containing low doses of lipoic acid-based active agents and methods for using the same are provided. In particular, compositions containing low dose lipoic acid, lipoic acid derivatives, said lipoic acid seleno-derivatives and are provided to prevent and/or treat ocular diseases.Type: GrantFiled: April 27, 2015Date of Patent: December 13, 2016Assignee: Encore Health, LLCInventors: William Garner, Margaret Garner
-
Patent number: 9326970Abstract: Compounds, formulations, and methods are provided containing the choline ester of a reducing agent, especially lipoic acid or derivatives thereof. The compounds may be administered via a topical ocular route to treat or prevent oxidative damage.Type: GrantFiled: October 28, 2014Date of Patent: May 3, 2016Assignee: Encore Health LLCInventors: William Garner, Margaret Garner, George Minno, David Gooden
-
Patent number: 9284305Abstract: Dithiol compounds and derivatives thereof are disclosed. The agents are useful for treating an ocular disease, especially presbyopia and cataract. Also provided are methods of treating an ocular disease, the methods comprising administering to a subject an active agent and an adjunctive agent.Type: GrantFiled: June 12, 2014Date of Patent: March 15, 2016Assignee: Encore Health, LLCInventors: William Garner, Margaret Garner, George Minno, David Gooden
-
Patent number: 9204996Abstract: This invention effects a change in the accommodation of the human lens affected by presbyopia through the use of various reducing agents that change accommodative abilities of the human lens, and/or by applying energy to affect a change in the accommodative abilities of the human lens. This invention both prevents the onset of presbyopia as well as treats it. By breaking and/or preventing the formation of bonds that adhere lens fibers together causing hardening of the lens, the present invention increases the elasticity and distensibility of the lens and/or lens capsule.Type: GrantFiled: May 12, 2014Date of Patent: December 8, 2015Assignee: Encore Health, LLCInventors: Jonathan S. Till, Ronald D. Blum
-
Patent number: 9161931Abstract: Dithiol compounds and derivatives thereof are disclosed. The agents are useful for treating ocular disease, especially presbyopia and cataract. Also disclosed are novel mercaptan compounds, particularly those including a photolabile protecting group, as well as methods of using the compounds for the prevention and treatment of ocular damage and disease.Type: GrantFiled: January 31, 2014Date of Patent: October 20, 2015Assignee: Encore Health, LLCInventors: William Garner, Margaret Garner, Ronald D. Blum
-
Patent number: 9044439Abstract: Compositions containing low doses of lipoic acid-based active agents and methods for using the same are provided. In particular, compositions containing low dose lipoic acid, lipoic acid derivatives, and lipoic acid seleno-derivatives and are provided to prevent and/or treat ocular diseases.Type: GrantFiled: November 7, 2008Date of Patent: June 2, 2015Assignee: Encore Health, LLCInventors: William Garner, Margaret Garner
-
Publication number: 20140336562Abstract: This invention effects a change in the accommodation of the human lens affected by presbyopia through the use of various reducing agents that change accommodative abilities of the human lens, and/or by applying energy to affect a change in the accommodative abilities of the human lens. This invention both prevents the onset of presbyopia as well as treats it. By breaking and/or preventing the formation of bonds that adhere lens fibers together causing hardening of the lens, the present invention increases the elasticity and distensibility of the lens and/or lens capsule.Type: ApplicationFiled: May 12, 2014Publication date: November 13, 2014Applicant: Encore Health, LLCInventors: Jonathan S. TILL, Ronald D. Blum
-
Publication number: 20140243385Abstract: Dithiol compounds and derivatives thereof are disclosed. The agents are useful for treating ocular disease, especially presbyopia and cataract. Also disclosed are novel mercaptan compounds, particularly those including a photolabile protecting group, as well as methods of using the compounds for the prevention and treatment of ocular damage and disease.Type: ApplicationFiled: January 31, 2014Publication date: August 28, 2014Applicant: Encore Health, LLCInventors: William GARNER, Margaret Garner, Ronald D. Blum
-
Patent number: 8795706Abstract: Methods of treating ocular diseases using dithiol compounds, their derivatives, and pharmaceutically acceptable salts thereof are disclosed. In particular, methods using dithiol compounds that comprise derivatives of lipoic acid are described. The dithiol compounds are especially useful for treating ocular diseases such as presbyopia and cataract.Type: GrantFiled: June 15, 2010Date of Patent: August 5, 2014Assignee: Encore Health, LLCInventors: William Garner, Margaret Garner, George Minno, Ronald D. Blum, David Gooden
-
Patent number: 8747829Abstract: This invention effects a change in the accommodation of the human lens affected by presbyopia through the use of various reducing agents that change accommodative abilities of the human lens, and/or by applying energy to affect a change in the accommodative abilities of the human lens. This invention both prevents the onset of presbyopia as well as treats it. By breaking and/or preventing the formation of bonds that adhere lens fibers together causing hardening of the lens, the present invention increases the elasticity and distensibility of the lens and/or lens capsule.Type: GrantFiled: February 16, 2011Date of Patent: June 10, 2014Assignee: Encore Health, LLCInventors: Jonathan S. Till, Ronald D. Blum
-
Publication number: 20140121266Abstract: Compounds, formulations, and methods are provided containing the choline ester of a reducing agent, especially lipoic acid or derivatives thereof. The compounds may be administered via a topical ocular route to treat or prevent oxidative damage.Type: ApplicationFiled: March 27, 2013Publication date: May 1, 2014Applicant: ENCORE HEALTH LLCInventors: William Garner, Margaret Garner, George Minno, David Gooden
-
Patent number: 8697109Abstract: Novel mercaptan compounds, particularly those including a photolabile protecting group, are described as well as methods of using the compounds for the prevention and treatment of ocular damage and disease.Type: GrantFiled: November 7, 2008Date of Patent: April 15, 2014Assignee: Encore Health, LLCInventors: William Garner, Margaret Garner, Ronald D. Blum
-
Patent number: 8647612Abstract: Dithiol compounds and derivatives thereof are disclosed. The agents are useful for treating ocular disease, especially presbyopia and cataract.Type: GrantFiled: February 23, 2009Date of Patent: February 11, 2014Assignee: Encore Health, LLCInventors: William Garner, Margaret Garner, Ronald D. Blum
-
Patent number: 8410162Abstract: Compounds, formulations, and methods are provided containing the choline ester of a reducing agent, especially lipoic acid or derivatives thereof. The compounds may be administered via a topical ocular route to treat or prevent oxidative damage.Type: GrantFiled: June 15, 2010Date of Patent: April 2, 2013Assignee: Encore Health LLCInventors: William Garner, Margaret Garner, George Minno, David Gooden
-
Patent number: 8147816Abstract: Embodiments of the present invention relate to methods and pharmacological or biological compositions to treat presbyopia in the human eye. According to the embodiments, pharmacological or biological compositions may be applied to or injected into an eye to effect a change in the accommodative ability of the eye by the breaking and reduction of lenticular bonds in the eye that may be responsible for presbyopia. The compositions may be applied in an inactive state and subsequently be activated to achieve a therapeutic effect. The application of energy may be used to either break the oxidized lenticular bonds and/or to activate one or more of the pharmacological or biological agents. The energy may be used in a focus treatment pattern to affect a change in the refractive characteristics of the eye and thereby reduce inherent optical distortions.Type: GrantFiled: November 28, 2007Date of Patent: April 3, 2012Assignee: Encore Health, LLCInventors: Jonathan S. Till, Ronald D. Blum, William R. Burns
-
Publication number: 20110135622Abstract: This invention effects a change in the accommodation of the human lens affected by presbyopia through the use of various reducing agents that change accommodative abilities of the human lens, and/or by applying energy to affect a change in the accommodative abilities of the human lens. This invention both prevents the onset of presbyopia as well as treats it. By breaking and/or preventing the formation of bonds that adhere lens fibers together causing hardening of the lens, the present invention increases the elasticity and distensibility of the lens and/or lens capsule.Type: ApplicationFiled: February 16, 2011Publication date: June 9, 2011Applicant: Encore Health, LLCInventors: Jonathan S. Till, Ronald D. Blum
-
Patent number: 7935332Abstract: This invention effects a change in the accommodation of the human lens affected by presbyopia through the use of various reducing agents that change accommodative abilities of the human lens, and/or by applying energy to affect a change in the accommodative abilities of the human lens. This invention both prevents the onset of presbyopia as well as treats it. By breaking and/or preventing the formation of bonds that adhere lens fibers together causing hardening of the lens, the present invention increases the elasticity and distensibility of the lens and/or lens capsule.Type: GrantFiled: December 14, 2004Date of Patent: May 3, 2011Assignee: Encore Health, LLCInventor: Jonathan S. Till
-
Patent number: 7914815Abstract: Embodiments of the present invention relate to a method for delivering pharmaceuticals to the lens of the eye to treat or prevent presbyopia. According to the embodiments, pharmaceuticals may be applied by providing the pharmaceuticals to the eye and promoting delivery of the pharmaceuticals into the lens capsule and/or lens fibers of the lens of the eye. Methods include iontophoresis, nano-medication, and photonic activation to deliver the pharmaceuticals to treat or prevent presbyopia.Type: GrantFiled: May 24, 2005Date of Patent: March 29, 2011Assignee: Encore Health, LLCInventors: Jonathan S. Till, Ronald D. Blum, William Kokonaski, Dwight P. Duston
-
Publication number: 20100317608Abstract: Dithiol compounds and derivatives thereof are disclosed. The agents are useful for treating ocular disease, especially presbyopia and cataract.Type: ApplicationFiled: June 15, 2010Publication date: December 16, 2010Applicant: Encore Health LLCInventors: William Garner, Margaret Garner, George Minno, Ronald D. Blum, David Gooden